CytomX Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q2 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
CytomX Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2015 to Q3 2024.
  • CytomX Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $61K, a 97.8% decline year-over-year.
  • CytomX Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $1.23M, a 56.4% decline year-over-year.
  • CytomX Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $3.89M.
  • CytomX Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $0.000.
  • CytomX Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.23M $61K -$2.76M -97.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $3.99M $51K +$51K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $3.94M $49K +$49K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $3.89M $1.07M +$1.07M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 $2.82M $2.82M +$2.82M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $0 $0 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $0 $0 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $0 $0 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-K 2023-03-27
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-K 2023-03-27
Q3 2020 -$14.3M $0 $0 Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-05
Q2 2020 -$14.3M $0 $0 Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-06
Q1 2020 -$14.3M -$13.9M* -$13.9M Jan 1, 2020 Mar 31, 2020 10-K/A 2023-03-27
Q4 2019 -$427K -$421K -$430K -4824% Oct 1, 2019 Dec 31, 2019 10-K/A 2023-03-27
Q3 2019 $2.91K $0 -$2.5M -100% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.5M $0 -$1.79M -100% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $4.3M -$6K -$1.1M -101% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $5.4M $8.91K +$528K Oct 1, 2018 Dec 31, 2018 10-K 2019-02-27
Q3 2018 $4.87M $2.5M +$2.52M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $2.35M $1.79M +$1.77M +6788% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $586K $1.1M +$1.1M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$513K -$519K -$493K -1896% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 -$20K -$19K -$20K -2000% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $0 $26K +$23K +767% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$23K -$1K -$4K -133% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$19K -$26K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $1K -$2K -66.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $3K -$2K -40% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 $3K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q3 2015 $3K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $5K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.